Resveratrol modulates adipokine expression and improves insulin sensitivity in adipocytes: Relative to inhibition of inflammatory responses

Biochimie

Volumn 92, Issue 7, 2010, Pages 789-796

  Kang, Liu ^a   Heng, Wang ^a   Yuan, An ^a   Baolin, Liu ^a   Fang, Huang ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Adipokine; Inflammation; Insulin resistance; Resveratrol

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; RESISTIN; RESVERATROL; SERINE; THREONINE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CULTURE MEDIUM; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LIPOPOLYSACCHARIDE; STILBENE DERIVATIVE;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; INFLAMMATION; INSULIN SENSITIVITY; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; 3T3 CELL LINE; ANIMAL; BIOSYNTHESIS; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECTS; GENETICS; INSULIN RESISTANCE; METABOLISM; PHARMACOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

3T3-L1 CELLS; ADIPOCYTES; ADIPOKINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; CULTURE MEDIA, CONDITIONED; GENE EXPRESSION REGULATION; GLUCOSE; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; PHOSPHORYLATION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STILBENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953536163     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.02.024     Document Type: Article

References (53)

1. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
2. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
3. Feinstein R., Kanety H., Papa M.Z., Lunenfeld B., Karasik A. Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J. Biol. Chem. 1993, 268:26055-26058.
4. Dandona P., Aljada A., Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004, 25:4-7.
5. Hotamisligil G.S., Arner P., Car J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 1995, 95:2409-2415.
6. Lagrue-Lak-Hal A.H., Andriantsitohaina R. Red wine and cardiovascular risks. Arch. Mal. Coeur Vaiss. 2006, 99:1230-1235.
7. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5:493-506.
8. Ma Z.H., Ma Q.Y., Wang L.C., Sha H.C., Wu S.L., Zhang M. Effect of resveratrol on NF-kappaB activity in rat peritoneal macrophages. Am. J. Chin. Med. 2006, 34:623-630.
9. Kowalski J., Samojedny A., Paul M., Pietsz G., Wilczok T. Effect of apigenin, kaempferol and resveratrol on the expression of interleukin-1beta and tumor necrosis factor-alpha genes in J774.2 macrophages. Pharmacol. Rep. 2005, 57:390-394.
10. Su H.C., Hung L.M., Chen J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E1339-E1346.
11. Lagouge M., Argmann C., Gerhart-Hines Z., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
12. Grimble R.F. Inflammatory status and insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care 2002, 5:551-559.
13. Cinti S., Mitchell G., Barbatelli G., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 2005, 46:2347-2355.
14. Hirasaka K., Kohno S., Goto J., et al. Deficiency of Cbl-b gene enhances infiltration and activation of macrophages in adipose tissue and causes peripheral insulin resistance in mice. Diabetes 2007, 56:2511-2522.
15. Arkan M.C., Hevener A.L., Greten F.R., et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 2005, 11:191-198.
16. Solinas G., Vilcu C., Neels J.G., et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab. 2007, 6:386-397.
17. De Taeye B.M., Novitskaya T., McGuinness O.P., et al. Macrophage TNF-alpha contributes to insulin resistance and hepatic steatosis in diet-induced obesity. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E713-E725.
18. Billack B., Radkar V., Adiabouah C. In vitro evaluation of the cytotoxic and anti-proliferative properties of resveratrol and several of its analogs. Cell. Mol. Biol. Lett. 2008, 13:553-569.
19. Radkar V., Lau-Cam C., Hardej D., et al. The role of surface receptor stimulation on the cytotoxicity of resveratrol to macrophages. Food Chem. Toxicol. 2008, 46:3664-3670.
20. de Luca C., Olefsky J.M. Inflammation and insulin resistance. FEBS Lett. 2008, 582:97-105.
21. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132:2169-2180.
22. Wang P., Mariman E., Renes J., Keijer J. The secretory function of adipocytes in the physiology of white adipose tissue. J. Cell. Physiol. 2008, 216:3-13.
23. Kern P.A., Ranganathan S., Li C., Wood L., Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2001, 280:E745-E751.
24. Pradhan A.D., Manson J.E., Rifai N., Burin J.E., Ridker P.M. C-Reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
25. Suganami T., Nishida J., Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb. Vasc. Biol. 2005, 25:2062-2068.
26. Fontana L., Eagon J.C., Trujillo M.E., et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56:1010-1013.
27. Fain J.N., Madan A.K., Hiler M.L., et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145:2273.
28. Ajuwon K.M., Spurlock M.E. Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPAR expression in adipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288:R1220-R1225.
29. Fasshauer M., Kralisch S., Klier M., et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2003, 301:1045-1050.
30. Muse E.D., Lam T.K., Scherer P.E., Rossetti L. Hypothalamic resistin induces hepatic insulin resistance. J. Clin. Invest. 2007, 117:1670-1678.
31. Meisner F., Walcher D., Gizard F., et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler Thromb. Vasc. Biol. 2006, 269:845-850.
32. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
33. Pang S.S., Le Y.Y. Role of resistin in inflammation and inflammation-related diseases. Cell. Mol. Immunol. 2006, 3:29-34.
34. Jackson M.B., Osei S.Y., Ahima R.S. The endocrine role of adipose tissue: focus on adiponectin and resistin. Curr. Opin. Endocrinol. Diabetes Obes. 2005, 12:163.
35. Rayalam S., Della-Fera M.A., Yang J.Y., et al. Resveratrol potentiates genistein's antiadipogenic and proapoptotic effects in 3T3-L1 adipocytes. J. Nutr. 2007, 137:2668-2673.
36. Park H.J., Yang J.Y., Ambati S., et al. Combined effects of genistein, quercetin, and resveratrol in human and 3T3-L1 adipocytes. J. Med. Food 2008, 11:773-783.
37. Yang J.Y., Della-Fera M.A., Rayalam S., et al. Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci. 2008, 82:1032-1039.
38. Yuan M., Konstantopoulos N., Lee J., et al. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikk. Science 2001, 293:1673-1677.
39. Tak P.P., Firestein G.S. NF-κB: a key role in inflammatory diseases. J. Clin. Invest. 2001, 107:7-11.
40. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
41. Altiel A.R., Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996, 45:1661-1669.
42. Ishizuka K., Usui I., Kanatani Y., et al. Chronic tumor necrosis factor-α treatment causes insulin resistance via insulin receptor substrate-1 serine phosphorylation and suppressor of cytokine signaling-3 induction in 3T3-L1 adipocytes. Endocrinology 2007, 148:2994-3003.
43. Herschkovitz A., Liu Y.F., Ilan E., Ronen D., Boura-Halfon S., Zick Y. Common inhibitory serine sites phosphorylated by IRS-1 kinases, triggered by insulin and inducers of insulin resistance. J. Biol. Chem. 2007, 282:18018-18027.
44. Gual P., Le Marchand-Brustel Y., Tanti J.F. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 2005, 87:99-109.
45. Lee Y.H., Giraud J., Davis R.J., White M.F. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J. Biol. Chem. 2003, 278:2896-2902.
46. Gao Z., Zuberi A., Quon M.J., et al. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J. Biol. Chem. 2003, 278:24944-24950.
47. Archuleta T.L., Lemieux A.M., Saengsirisuwan V., et al. Oxidant stress-induced loss of IRS-1 and IRS-2 proteins in rat skeletal muscle: role of p38 MAPK. Free Radic. Biol. Med. 2009, 47:1486-1493.
48. Liu J., Shen W., Zhao B., et al. Targeting mitochondrial biogenesis for preventing and treating insulin resistance in diabetes and obesity: hope from natural mitochondrial nutrients. Adv. Drug Deliv. Rev. 2009, 61:1343-1352.
49. Fisher-Wellman K., Bloomer R.J. Macronutrient specific postprandial oxidative stress: relevance to the development of insulin resistance. Curr. Diabetes Rev. 2009, 5:228-238.
50. Fridlyand L.E., Philipson L.H. Reactive species, cellular repair and risk factors in the onset of type 2 diabetes mellitus: review and hypothesis. Curr. Diabetes Rev. 2006, 2:241-259.
51. Brisdelli F., D'Andrea G., Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr. Drug Metab. 2009, 10:530-546.
52. Ungvari Z., Labinskyy N., Mukhopadhyay P., et al. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H1876-H1881.
53. Deng J.Y., Hsieh P.S., Huang J.P., et al. Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways. Diabetes 2008, 57:1814-1823.